Expression of platelet-derived growth factor-alpha receptor and c-kit in giant cell tumours of bone

Pathology

Volumn 41, Issue 7, 2009, Pages 630-633

  Sulzbacher, Irene ^a   Dominkus, Martin ^a   Pichlhofer, Bettina ^a   Mazal, Peter R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

C kit; Giant cell tumour of bone; PDGFRA

Indexed keywords

GENOMIC DNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CURETTAGE; DNA EXTRACTION; DNA SEQUENCE; EXON; FEMALE; FEMUR; FIBULA; FOLLOW UP; HUMAN; HUMAN TISSUE; HUMERUS; ILIAC BONE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG METASTASIS; MALE; MUTATION; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOMA; PHALANX; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RADIUS; TIBIA; TUMOR GROWTH; TUMOR LOCALIZATION;

EID: 72749091933     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313020903257749     Document Type: Article

References (26)

1. Fletcher CDM, Unni KK, Mertens F. Pathology and Genetics of Tumours of Soft Tissue and Bone. 1st ed. Lyon: IARC Press, 2002; 310-313
2. Dorfmann HD, Czerniak B. Bone Tumors. 1st ed. St Louis: Mosby, 1998; 559-598
3. Haque AU, Moatasim A. Giant cell tumor of bone: A neoplasm or a reactive condition? Int J Clin Exp Pathol 2008; 1: 489-501.
4. Guenther R, Krenn V, Morawietz L, et al. Giant cell tumors of the bone: Molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. Pathol Res Pract 2005; 201: 649-663
5. Zheng MH, Robbins P, Xu J, et al. The histogenesis of giant cell tumour of bone:a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 2001; 16: 297-307.
6. Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer 2003; 97: 2520-2529 (Pubitemid 36542492)
7. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-5364
8. de Mestier P, des Guetz G. Treatment of gastrointestinal stroma tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics. World J Surg 2005; 29: 357-361
9. Baselga J, Arribas J. Treating cancer's kinase 'addiction'. Nat Med 2004; 10: 786-787
10. Won Kim T, Lee H, Kang YK, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004; 10: 3076-3081
11. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutation analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40: 689-695
12. Sulzbacher I, Träxler M, Mosberger I, et al. Platelet-derived growth factor-AA and -a receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 2000; 13: 632-637
13. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-1316
14. Gamberi G, Serra M, Ragazzini P, et al. Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep 2003; 10: 351-356
15. Gamberi G, Benassi MS, Ragazzini P, et al. Proteases and interleukin- 6 gene analysis in 92 giant cell tumors of bone. Ann Oncol 2004; 15: 498-503.
16. Horvai AE, Kramer MJ, Garcia JJ, et al. Distribution and prognostic significance of human telomerase reverse transcriptase (hTERT) expression in giant-cell tumor of bone. Mod Pathol 2008; 21: 423-430
17. Cheng YY, Huang L, Kumta SM, et al. Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration. Ultrastruct Pathol 2003; 27: 385-391
18. Cheng YY, Huang L, Lee KM, et al. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 2004; 75: 71-77 (Pubitemid 38989221)
19. Atkins GJ, Hayes DR, Graves SE, et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000; 15: 640-649
20. Lau YS, Sabokbar A, Gibbons CL, et al. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005; 36: 945-954
21. Hamdy NA. Densosumab: RANKL inhibition in the management of bone loss. Drugs Today 2008; 44: 7-21.
22. Morgan T, Atkins GJ, Trivett MK, et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kB. Am J Pathol 2005; 167: 117-128
23. Sulzbacher I, Birner P, Toma C, et al. Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker. J Clin Pathol 2007; 60: 804-807
24. Wei H, Zhao MQ, Dong W, et al. Expression of c-kit protein and mutation status of the c-kit gene in osteosarcoma and their clinicopathological significance. Int Med Res 2008; 36: 1008-1014
25. Kuba T, Piperdi S, Rosenblum J, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008; 112: 2119-2129
26. Entz-Werle N, Gaub MP, Lavaux T, et al. KIT gene in pediatric osteosarcomas: could it be a new therapeutic target? Int J Cancer 2007; 120: 2510-2516